Novo obesity strategy as Eli Lilly extends lead

Key Points:

• Novo Nordisk unveiled an ambitious strategy to diversify beyond its leading obesity and diabetes drugs Wegovy and Ozempic, aiming to launch multiple blockbuster products by 2030, but investors remain skeptical due to growth targets that only match industry averages and unclear near-term plans.
• Eli Lilly continues to erode Novo's market share, especially in the obesity pill segment, with its Foundayo pill gaining traction and capturing about 70% of Medicare patients starting GLP-1 treatments, bolstered by strong commercial capabilities and newer drugs like Zepbound.
• Analysts predict Lilly will maintain its leadership in the obesity drug market due to its global reach, advanced pipeline—including next-generation drugs like retatrutide and amylin receptor-targeting injections—and greater manufacturing scalability of its small-molecule oral drugs.
• Novo is betting heavily on a broad future pipeline with over five potential multi-blockbuster drugs by 2030 and plans to increase patient capacity tenfold, but faces challenges convincing investors amid past clinical setbacks and concerns over sustaining premium pricing post-patent expiry in 2032.
• Both companies are focusing on expanding the obesity drug market, with Novo targeting 15 million oral treatment users by 2030 and emphasizing patient options and drug tolerability, while Lilly leverages its commercial firepower and drug efficacy to grow its dominant market position.